Formulation Development
Evonik Launches Ready-to-Use Powder Premix to Improve Processing, Appearance & Swallowability of Oral Drug Products With an Immediate-Release Profile
Evonik recently launched a new ready-to-use powder premix blend of its EUDRAGIT functional polymers used for oral products with an immediate-release profile. EUDRAGIT IR ReadyMix…
Bayer Acquires Company to Broaden Innovation Base in Cell & Gene Therapy
Bayer AG recently announced the acquisition of Asklepios BioPharmaceutical, Inc., a US-headquartered biopharmaceutical company specialized in the research, development, and manufacturing of gene therapies across different therapeutic areas…..
Lonza Significantly Expands Its Capsule Manufacturing Capacity
Lonza recently announced a $93-million investment in its Capsules and Health Ingredients (CHI) Division, a dosage form delivery partner to the biopharma and health nutrition industry…..
Quantum Genomics Enters Exclusive Licensing & Collaboration Agreement With Qilu Pharmaceutical
Quantum Genomics recently announced it has entered into an exclusive licensing and collaboration agreement with Qilu Pharmaceutical to develop and commercialize….
NGM Expands Oncology Portfolio With First Immuno-Oncology Development Candidate
NGM Biopharmaceuticals, Inc. recently announced the expansion of its oncology portfolio with its first immuno-oncology development candidate….
Catalent Launches Delayed/Enteric-Release Softgel for Pharmaceutical & Nutraceutical Applications
Catalent recently announced the launch of OptiGel DR technology for the formulation and manufacture of delayed/enteric-release softgels. The technology allows softgel capsules to be formed…
BrainStorm Cell Therapeutics & Catalent Announce Manufacturing Partnership
Catalent and BrainStorm Cell Therapeutics Inc. recently announced an agreement for the manufacture of NurOwn, BrainStorm’s autologous cellular therapy being investigated for the treatment of….
VBL Therapeutics Announces Additional New European Patent
VBL Therapeutics recently announced the European Patent Office (EPO) has granted Patent No. 3328401, which covers VBL’s proprietary investigational anti-MOSPD2 monoclonal antibodies to treat oncology…
First Patient Dosed in Phase 2 Trial to Treat Complications in COVID-19
Arch Biopartners Inc. recently announced it has dosed the first patient in the Phase 2 trial of its lead drug LSALT peptide, targeting prevention of…
PepTC Vaccines Publishes Positive Preclinical Results for COVID-19 Peptide Vaccine
PepTC Vaccines Limited, a subsidiary of Treos Bio Limited, recently announced the publication of positive preclinical results of its investigational PolyPEPI-SCoV-2 peptide vaccine. The study…
Castle Creek Biosciences Treats First Patient in Phase 1/2 Gene Therapy Trial
Castle Creek Biosciences, Inc. recently announced that the first adult patient has been dosed in a Phase 1/2 clinical trial evaluating FCX-013, the company’s investigational…
Beroni Group Announces Successful Completion of SARS-CoV-2 Pseudovirus Neutralization Assay for Treatment of COVID-19
Beroni Group recently announced successful completion of SARS-CoV-2 pseudovirus neutralization assay in collaboration with GenScript Biotech Corporation (HKSE:1548), a leading global biotechnology company. The assay…
Aptose Initiates Dosing of CG-806 in Patients With Acute Myeloid Leukemia
Aptose Biosciences Inc. recently announced dosing of the first patient with acute myeloid leukemia (AML) in a Phase 1 a/b clinical study with CG-806, the…
WHITE PAPER: Outsourcing Analytical Testing for Biologics
Analytical testing required to support CMC activities of biologics is highly sophisticated, and is becoming more so as the modalities of….
WEBINAR ALERT: Stability Testing as Quality Control Measure: Optimizing the Process Throughout the Product Lifecycle
Assessing a compound’s stability is a complex and lengthy process with objectives varying by the development phase…..
MilliporeSigma’s New Platform Speeds Development of Cell & Gene Therapies
MilliporeSigma has recently bolstered its viral vector manufacturing capabilities with the launch of its VirusExpress Lentiviral Production Platform…..
Marinomed Biotech AG Develops First Medicinal Product for Autoimmune Gastritis
Marinomed Biotech AG, a Vienna-based biopharmaceutical company, develops groundbreaking treatment for autoimmune gastritis together with the Medical University of….
Cytovia Therapeutics Partners Enters Research & Licensing Agreement With Inserm
Cytovia Therapeutics recently announced it has entered a research and licensing agreement with Inserm to develop NK engager bi-specific antibodies and iPSC CAR NK cell therapy targeting….
Takeda & Arrowhead Collaborate to Co-Develop & Co-Commercialize ARO-AAT for Alpha-1 Antitrypsin-Associated Liver Disease
Takeda Pharmaceutical Company Limited and Arrowhead Pharmaceuticals Inc. recently announced a collaboration and licensing agreement to develop ARO-AAT, a Phase 2 investigational RNA interference (RNAi)…
Vaxart Announces Dosing First Subject in Phase 1 Clinical Trial of Its Oral Tablet COVID-19 Vaccine
Vaxart, Inc. recently announced the first subject has been dosed in its Phase 1 study of VXA-CoV2-1, an oral tablet COVID-19 vaccine candidate. “We are…
